For citations:
Kuzenkova L.M., Kurenkov A.L., Uvakina E.V., Fisenko D.A., Chernikov V.V., Semikina E.L., Popovich S.G., Bursagova B.I., Globa O.V., Andreenko N.V., Abdullaeva L.M., Kurova J.A., Adalimova N.S., Nikolenko D.S., Lyalina A.A., Komarova O.V. Results of a two-year comprehensive follow-up in patients with spinal muscular atrophy who received gene therapy with onasemnogen abeparvovec at the presymptomatic stage of the disease. L.O. Badalyan Neurological Journal. 2025;6(4):182-194. (In Russ.) https://doi.org/10.46563/2686-8997-2025-6-4-182-194. EDN: bletts
JATS XML



















